|
1.
|
|
17 p, 1.2 MB |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
/
Munir, Talha (St James's Hospital) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Benjamini, Ohad (Sheba Medical Center) ;
Janssens, Ann (UZ Leuven Gasthuisberg) ;
Levin, Mark-David (Albert Schweitzer Hospital) ;
Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Stevens, Don (Norton Cancer Institute) ;
Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ;
Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ;
Yagci, Munci (Gazi Universitesi Tip Fakultesi) ;
Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ;
Qi, Keqin (Janssen Research & Development) ;
Qi, Qianya (Janssen Research & Development) ;
Parisi, Lori (Janssen Research & Development) ;
Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ;
Schuier, Natasha (Janssen Research & Development) ;
Baeten, Kurt (Janssen Research & Development) ;
Howes, Angela (Janssen Research & Development) ;
Caces, Donne Bennett (Janssen Research & Development) ;
Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ;
Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 -  10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699
|
|
|
2.
|
|
34 p, 1.3 MB |
Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents : Kinetic characterization and effect on human cancer cells
/
Jiménez, Rafael (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Pequerul, Raquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Amor Minguez, Adrián (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Lorenzo Rivera, Julia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Metwally, Kamel (Zagazig University. Department of Medicinal Chemistry) ;
Avilés, Francesc X (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Parés i Casasampera, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Farrés, Jaume (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Aldehyde dehydrogenases (ALDHs) are enzymes catalyzing the NAD(P)+-dependent oxidation of aldehydes to their corresponding carboxylic acids. High ALDH activity has been related to some important features of cancer stem cells. [...]
2019 - 10.1016/j.cbi.2019.04.004
Chemico-Biological Interactions, Vol. 306 (2019) , p. 123-130
|
|
|
3.
|
|
15 p, 3.3 MB |
Methuosis Contributes to Jaspine-B-Induced Cell Death
/
Bielsa, Núria (Institut de Química Avançada de Catalunya) ;
Casasampere, Mireia (Institut de Química Avançada de Catalunya) ;
Abad, José Luis (Institut de Química Avançada de Catalunya) ;
Enrich, Carlos (Universitat de Barcelona. Departament de Biomedicina) ;
Delgado, Antonio (Institut de Química Avançada de Catalunya) ;
Fabriàs, Gemma (Institut de Química Avançada de Catalunya) ;
Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Casas, Josefina (Institut de Química Avançada de Catalunya)
Methuosis is a type of programmed cell death in which the cytoplasm is occupied by fluid-filled vacuoles that originate from macropinosomes (cytoplasmic vacuolation). A few molecules have been reported to behave as methuosis inducers in cancer cell lines. [...]
2022 - 10.3390/ijms23137257
International journal of molecular sciences, Vol. 23 Núm. 13 (2022) , p. 7257
|
|
|
4.
|
|
14 p, 3.9 MB |
Combined analysis of miR-200 family and its significance for breast cancer
/
Fontana, Andrea (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Barbano, Raffaela (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Dama, Elisa (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Pasculli, Barbara (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Rendina, Michelina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Morritti, Maria Grazia (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Melocchi, Valentina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Castelvetere, Marina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Valori, Vanna Maria (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Ravaioli, Sara (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Bravaccini, Sara (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Ciuffreda, Luigi (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Graziano, Paolo (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Maiello, Evaristo (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Copetti, Massimiliano (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Fazio, Vito Michele (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bianchi, Fabrizio (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Parrella, Paola (Fondazione IRCCS Casa Sollievo della Sofferenza)
While the molecular functions of miR-200 family have been deeply investigated, a role for these miRNAs as breast cancer biomarkers remains largely unexplored. In the attempt to clarify this, we profiled the miR-200 family members expression in a large cohort of breast cancer cases with a long follow-up (H-CSS cohort) and in TCGA-BRCA cohort. [...]
2021 - 10.1038/s41598-021-82286-1
Scientific reports, Vol. 11 Núm. 1 (december 2021) , p. 2980
|
|
|
5.
|
|
14 p, 5.6 MB |
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
/
Romero, Octavio A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vilarrubi, Andrea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Alburquerque-Béjar, Juan Jos (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gómez Moruno, Antonio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrades, Álvaro (Universidad de Granada) ;
Trastulli, Deborah (Institut d'Investigació Biomèdica de Bellvitge) ;
Pros, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Setien, Fernando (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Verdura, Sara (Institut d'Investigació Biomèdica de Bellvitge) ;
Farre, Lourdes (Institut d'Investigació Biomèdica de Bellvitge) ;
Martín-Tejera, Juan F. (Institut d'Investigació Biomèdica de Bellvitge) ;
Llabata, Paula (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Oaknin, Ana (Hospital Universitari Vall d'Hebron) ;
Saigi, María (Institut Català d'Oncologia) ;
Piulats, Josep M. (Institut Català d'Oncologia) ;
Matias-Guiu, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Medina, Pedro P. (Universidad de Granada) ;
Vidal, August (Parc Científic de Barcelona) ;
Villanueva, Alberto (Parc Científic de Barcelona) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. [...]
2021 - 10.1038/s41467-021-24618-3
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 4319
|
|
|
6.
|
|
10 p, 1.1 MB |
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
/
Ljungman, Per (Karolinska Institutet (Estocolm, Suècia)) ;
de la Camara, Rafael (Hospital Universitario de la Princesa (Madrid)) ;
Mikulska, Malgorzata (Division of Infectious Diseases. University of Genoa and Ospedale Policlinico San Martino) ;
Tridello, G. (Pediatric Hematology Oncology) ;
Aguado, Beatriz (Instituto de Investigación Hospital Universitario de la Princesa) ;
Zahrani, M.A. (King Abdul - Aziz Medical City) ;
Apperley, Jane (Centre for Haematology. Imperial College) ;
Berceanu, A. (Hopital Jean Minjoz) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciceri, Fabio (Ospedale San Raffaele s.r.l.) ;
Lopez-Corral, L. (Hematology Department. Complejo Asistencial Universitario de Salamanca-IBSAL; Centro de Investigación del Cáncer-IBMCC) ;
Crippa, C. (Spedali Civili) ;
Fox, M.L. (Vall d'Hebron Institut d'Oncologia) ;
Grassi, A. (ASST Papa Giovanni XXIII) ;
Jimenez, M.J. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Demir, S.K. (HSCT unit. Demiroglu Bilim University) ;
Kwon, Mi (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Llamas, C.V. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Lorenzo, J.L.L. (Hospital Universitario Fundación Jiménez Díaz) ;
Mielke, S. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Orchard, K. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Porras, R.P. (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Vallisa, D. (Hospital Guglielmo da Saliceto) ;
Xhaard, A. (Hôpital St. Louis) ;
Knelange, N.S. (EBMT Data Office. Department of Medical Statistics & Bioinformatics) ;
Cedillo, Angel (GETH Spanish Registry) ;
Kroeger, Nicolaus (Department of Stem cell Transplantation. University Hospital Eppendorf) ;
Piñana, José Luis (Hospital Clínic Universitari (València)) ;
Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum. Nicolaus Copernicus University Torun)
This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). [...]
2021 - 10.1038/s41375-021-01302-5
Leukemia, Vol. 35 Núm. 10 (october 2021) , p. 2885-2894
|
|
|
7.
|
|
15 p, 664.9 KB |
Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
/
Wierda, W. G. (University of Texas.) ;
Allan, J. N. (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, T. J. (UCSD. Moores Cancer Center) ;
Opat, S. (Monash University) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Badoux, X. C. (Ministry of Health) ;
Kuss, B. J. (Flinders University. Medical Centre) ;
Jackson, Sharon (Middlemore Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Jacobs, R. M. D. (Levine Cancer Institute) ;
Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ;
Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ;
Pak, Y. (Pharmacyclics LLC. AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ;
Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ;
Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ;
Dean, James P (Pharmacyclics LLC. AbbVie Company) ;
James, D. F. (Pharmacyclics LLC. AbbVie Company) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ;
Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ;
Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865
|
|
|
8.
|
|
6 p, 785.8 KB |
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
/
Bobillo, Sabela (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Joffe, Erel (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Sermer, David (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Mondello, Patrizia (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Ghione, Paola (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Caron, Philip C. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Hamilton, Audrey (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Hamlin, Paul A. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Horwitz, Steven M. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Kumar, Anita (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Matasar, Matthew J. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Batlevi, Connie L. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Moskowitz, Alison (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Noy, Ariela (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Owens, Collette N. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Palomba, M. Lia (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Straus, David (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
von Keudell, Gottfried (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Dogan, Ahmet (Memorial Sloan Kettering Cancer Center. Department of Pathology) ;
Zelenetz, Andrew D. (Weill Cornell Medical College. Weill Cornell Department of Medicine) ;
Seshan, Venkatraman E. (Memorial Sloan Kettering Cancer Center) ;
Younes, Anas (Weill Cornell Medical College. Weill Cornell Department of Medicine)
Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear. We examined the efficacy of different prophylactic regimens in 585 patients with newly diagnosed DLBCL and high-risk for CNS relapse, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like regimens from 2001 to 2017, of whom 295 (50%) received prophylaxis. [...]
2021 - 10.1038/s41408-021-00506-3
Blood Cancer Journal, Vol. 11 (june 2021)
|
|
|
9.
|
|
22 p, 4.5 MB |
Transient reprogramming of postnatal cardiomyocytes to a dedifferentiated state
/
Kisby, Thomas (University of Manchester. Nanomedicine Lab) ;
de Lázaro, Irene (University of Manchester. Nanomedicine Lab) ;
Stylianou, Maria (University of Manchester. Nanomedicine Lab) ;
Cossu, Giulio (University of Manchester. Division of Cell Matrix Biology and Regenerative Medicine) ;
Kostarelos, Kostas (Institut Català de Nanociència i Nanotecnologia)
In contrast to mammals, lower vertebrates are capable of extraordinary myocardial regeneration thanks to the ability of their cardiomyocytes to undergo transient dedifferentiation and proliferation. Somatic cells can be temporarily reprogrammed to a proliferative, dedifferentiated state through forced expression of Oct3/4, Sox2, Klf4 and c-Myc (OSKM). [...]
2021 - 10.1371/journal.pone.0251054
PloS one, Vol. 16, Issue 5 (May 2021) , p. e0251054
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
